Skip to content

A clinical trial to asses the effects of combination of drugs (Ibuprofen and paracetamol) with single drug (paracetamol) in the closure of Patent ductus arteriosus in preterm neonates admitted to neonatal intensive care unit.

A study to compare combined drugs therapy of Ibuprofen and Paracetamol with monotherapy of Paracetamol in treating hemodynamic significant Patent ductus arteriosus (HsPDA) in preterm infants. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/0106419
Enrollment
54
Registered
2026-03-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P293- Persistent fetal circulation

Interventions

Sponsors

Aditya Kurade
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Gestational age more than 26 weeks to less than 37 weeks. Birth weight more than 500 grams and less than 2000 grams. Echocardiographic Evidence of Hemodynamic significant PDA - PDA diameter more than 1.5 mm, PDA doppler flow pattern left to right (Growing and pulsatile pattern), LA/AO ratio more than 1.5 .

Exclusion criteria

Exclusion criteria: Chromosomal anomalies suspected or proven Significant congenital malformation Complex congenital heart disease Severe Birth asphyxia Severe Persistent pulmonary hypertension (PPHN) Previously treated for PDA Contraindications for Ibuprofen administration (any of following) - Acute kidney injury (Oliguria urine output less than 1 ml/kg/24 hours and or Raised serum creatinine level more than 1 mg/dl), Increased hepatic enzyme (two fold raised than baseline level), severe hyperbilirubinemia (serum bilirubin nearing exchange level), Thrombocytopenia (Platelet count less than 50,000/cumm), Acute or suspected Necrotising Enterocolitis (As per Bell s staging), acute bleeding - Pulmonary hemorrhage, Intraventricular hemorrhage, Gastrointestinal bleeding.

Design outcomes

Primary

MeasureTime frame
Hemodynamic significant PDA resolution or PDA closureTimepoint: Baseline, 5 days and 10 days

Secondary

MeasureTime frame
Any Adverse drug effectsTimepoint: Till 7 days after completion of drug therapy

Countries

India

Contacts

Public ContactAditya Vijay Kurade

Bharati Vidyapeeth (Deemed to be University) Medical college and Hospital, Sangli.

kurade.aditya@gmail.com9096806123

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026